Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
Raquib Alam, Shantanu Kumar, Rohit Shukla, Nisha Chaudhary, Juli Gupta, Akshita Sinha, Rituparna Chaudhuri, Mohan Ranganathan, Kashif Husain, Nisar Rahim Shaikh, Deeksha Joshi, Jahnvi Hora, Syed Ahmad Ali, Subhankar Bose, Prasad Iyer, , Tanveer Ahmad
This paper develops viroVbot, an in vivo CAR-T platform with reduced immunogenicity and safety, showing efficacy in treating multiple myeloma and gastric cancer through sequential redosing.
bioRxiv · Jul 2, 2026 · PreprintBioengineering